Nasdaq or NYSE related Health Care sector Top Companies List by Market Cap as of January 2024

Nasdaq or NYSE listed Health Care sector Top Companies List by Market Cap as of Jan-05-2024. Nasdaq and NYSE related Health Care sector Largest Companies List by Market Cap as of Jan-05-2024

  1. Cytek Biosciences Inc.

    World Rank (Jan-05-2024)
    8,052
    Market Cap (Jan-05-2024)
    1.112 Billion USD
    World Rank (Jul-30-2023)
    7,760
    Market Cap (Jul-30-2023)
    1.220 Billion USD
    World Rank (Dec-25-2022)
    6,961
    Market Cap (Dec-25-2022)
    1.365 Billion USD
    World Rank (Jan-07-2022)
    6,109
    Market Cap (Jan-07-2022)
    2.09 Billion USD
    Annual Revenue in USD
    164 Million USD
    Annual Operating Income in USD
    -2 Million USD
    Annual Net Income in USD
    3 Million USD
    Annual Results for Period Ending
    Dec-2022 ending year
    Headquarters Country
    USA
    Yahoo @ Nasdaq
    Company Profile
    Cytek Biosciences, INC is a Cell Analysis to Fuel Scientific Discovery company focused on cancer biology, immunology and genomics. The company annual revenue is 128 million USD  as on 2021. The headquarters is in USA.
    Company Website
    CYTEK BIOSCIENCES, INC.

  2. Embecta Corp.

    World Rank (Jan-05-2024)
    8,300
    Market Cap (Jan-05-2024)
    1.061 Billion USD
    World Rank (Jul-30-2023)
    7,763
    Market Cap (Jul-30-2023)
    1.219 Billion USD
    World Rank (Dec-25-2022)
    6,371
    Market Cap (Dec-25-2022)
    1.571 Billion USD
    Headquarters Country
    USA
    Company Website
    EMBECTA CORP.

  3. Kymera Therapeutics Inc.

    World Rank (Jan-05-2024)
    6,735
    Market Cap (Jan-05-2024)
    1.510 Billion USD
    World Rank (Jul-30-2023)
    7,820
    Market Cap (Jul-30-2023)
    1.208 Billion USD
    World Rank (Dec-25-2022)
    6,679
    Market Cap (Dec-25-2022)
    1.453 Billion USD
    World Rank (Jan-07-2022)
    5,018
    Market Cap (Jan-07-2022)
    2.86 Billion USD
    Annual Revenue in USD
    47 Million USD
    Annual Operating Income in USD
    -154 Million USD
    Annual Net Income in USD
    -154 Million USD
    Annual Results for Period Ending
    Dec-2022 ending year
    Headquarters Country
    USA
    Yahoo @ Nasdaq
    Company Profile
    Kymera is a Biopharmaceutical company. It is a developing novel protein degrader therapeutics to treat disease in powerful new ways which harness the body's natural protein degradation system to selectively degrade disease causing proteins with the goal of completely removing them from the body. The company annual revenue is 10.4 million USD and 67 employees as on 2019. The headquarters is in USA.
    Company Website
    KYMERA THERAPEUTICS, INC.

  4. Arvinas

    World Rank (Jan-05-2024)
    5,263
    Market Cap (Jan-05-2024)
    2.279 Billion USD
    World Rank (Jul-30-2023)
    7,862
    Market Cap (Jul-30-2023)
    1.197 Billion USD
    World Rank (Dec-25-2022)
    5,940
    Market Cap (Dec-25-2022)
    1.741 Billion USD
    World Rank (Jan-07-2022)
    4,198
    Market Cap (Jan-07-2022)
    3.65 Billion USD
    Annual Revenue in USD
    131 Million USD
    Annual Operating Income in USD
    -263 Million USD
    Annual Net Income in USD
    -282 Million USD
    Annual Results for Period Ending
    Dec-2022 ending year
    Headquarters Country
    USA
    Yahoo @ Nasdaq
    Company Profile

    Arvinas is a Clinical Stage Biopharmaceutical company. It is focused on developing new therapeutics for cancers and other difficult to treat diseases and on high value targets in cancer including the androgen and estrogen receptors associated with prostate and breast cancers, respectively. The headquarters is in USA.

    Company Website
    ARVINAS

  5. CymaBay Therapeutics

    World Rank (Jan-05-2024)
    4,829
    Market Cap (Jan-05-2024)
    2.607 Billion USD
    World Rank (Jul-30-2023)
    7,868
    Market Cap (Jul-30-2023)
    1.197 Billion USD
    World Rank (Dec-25-2022)
    12,906
    Market Cap (Dec-25-2022)
    0.464 Billion USD
    World Rank (Jan-07-2022)
    17,152
    Market Cap (Jan-07-2022)
    0.28 Billion USD
    Annual Revenue in USD
    0 Million USD
    Annual Operating Income in USD
    -93 Million USD
    Annual Net Income in USD
    -106 Million USD
    Annual Results for Period Ending
    Dec-2022 ending year
    Headquarters Country
    USA
    Yahoo @ Frankfurt
    Company Profile
    CymaBay Therapeutics is a Clinical Stage Biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. The company estimated annual revenue is currently 6.8 million USD per year. The headquarters is in USA.
    Company Website
    CYMABAY THERAPEUTICS

  6. Ligand Pharmaceuticals

    World Rank (Jan-05-2024)
    7,621
    Market Cap (Jan-05-2024)
    1.227 Billion USD
    World Rank (Jul-30-2023)
    7,940
    Market Cap (Jul-30-2023)
    1.175 Billion USD
    World Rank (Dec-25-2022)
    5,769
    Market Cap (Dec-25-2022)
    1.822 Billion USD
    World Rank (Jan-07-2022)
    5,576
    Market Cap (Jan-07-2022)
    2.42 Billion USD
    Annual Revenue in USD
    196 Million USD
    Annual Operating Income in USD
    3 Million USD
    Annual Net Income in USD
    -33 Million USD
    Annual Results for Period Ending
    Dec-2022 ending year
    Headquarters Country
    USA
    Yahoo @ Nasdaq
    Company Profile
    Ligand Pharmaceuticals is a Biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It is providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. The headquarters is in USA.
    Company Website
    LIGAND PHARMACEUTICALS INCORPORATED

  7. Replimune Group

    World Rank (Jan-05-2024)
    12,365
    Market Cap (Jan-05-2024)
    0.520 Billion USD
    World Rank (Jul-30-2023)
    7,950
    Market Cap (Jul-30-2023)
    1.172 Billion USD
    World Rank (Dec-25-2022)
    7,081
    Market Cap (Dec-25-2022)
    1.332 Billion USD
    World Rank (Jan-07-2022)
    8,400
    Market Cap (Jan-07-2022)
    1.22 Billion USD
    Annual Revenue in USD
    0 Million USD
    Annual Net Income in USD
    -118 Million USD
    Annual Results for Period Ending
    Mar-2022 ending year
    Headquarters Country
    USA
    Yahoo @ Frankfurt
    Company Profile

    Replimune Group is an emerging class of Cancer Therapeutics company that exploits the ability of viruses to selectively replicate in and kill tumors while at the same time inducing a potent, patient specific, anti tumor immune response. The headquarters is in USA.

    Facts About Company

    Replimune Group Annual Net loss for year ending Mar-2023 was -174 million USD.

    Replimune Group Annual Net loss for year ending Mar-2022 was -118 million USD.

    As on 2023, Replimune Group has 284 employees.

    Company Website
    REPLIMUNE GROUP

  8. Adaptive Biotechnologies Corporation

    World Rank (Jan-05-2024)
    10,807
    Market Cap (Jan-05-2024)
    0.673 Billion USD
    World Rank (Jul-30-2023)
    7,981
    Market Cap (Jul-30-2023)
    1.165 Billion USD
    World Rank (Dec-25-2022)
    8,035
    Market Cap (Dec-25-2022)
    1.073 Billion USD
    World Rank (Jan-07-2022)
    4,537
    Market Cap (Jan-07-2022)
    3.27 Billion USD
    Annual Revenue in USD
    185 Million USD
    Annual Operating Income in USD
    -200 Million USD
    Annual Net Income in USD
    -200 Million USD
    Annual Results for Period Ending
    Dec-2022 ending year
    Headquarters Country
    USA
    Yahoo @ Nasdaq
    Company Profile

    Adaptive Biotechnologies Corporation is a Life Science Equipment and Technology company. The company products and services of both current and pipeline, supporting life sciences research, clinical diagnostics and drug discovery, aim is to add an entirely new dimension to the diagnosis and treatment of disease from cancer to autoimmune conditions to infectious diseases. The headquarters is in USA.

    Company Website
    ADAPTIVE BIOTECHNOLOGIES CORPORATION

  9. 89Bio Inc.

    World Rank (Jan-05-2024)
    8,293
    Market Cap (Jan-05-2024)
    1.062 Billion USD
    World Rank (Jul-30-2023)
    7,991
    Market Cap (Jul-30-2023)
    1.162 Billion USD
    World Rank (Dec-25-2022)
    12,003
    Market Cap (Dec-25-2022)
    0.532 Billion USD
    World Rank (Jan-07-2022)
    17,461
    Market Cap (Jan-07-2022)
    0.26 Billion USD
    Annual Revenue in USD
    0 Million USD
    Annual Operating Income in USD
    -102 Million USD
    Annual Net Income in USD
    -102 Million USD
    Annual Results for Period Ending
    Dec-2022 ending year
    Headquarters Country
    USA
    Yahoo @ Nasdaq
    Company Profile

    89bio is a Clinical Stage Biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio metabolic diseases. The headquarters is in USA.

    Company Website
    89BIO

  10. Inhibrx Inc.

    World Rank (Jan-05-2024)
    6,046
    Market Cap (Jan-05-2024)
    1.809 Billion USD
    World Rank (Jul-30-2023)
    7,998
    World Rank (Dec-25-2022)
    7,998
    Market Cap (Dec-25-2022)
    1.081 Billion USD
    World Rank (Jan-07-2022)
    8,138
    Market Cap (Jan-07-2022)
    1.29 Billion USD
    Annual Revenue in USD
    7,125 Million USD
    Annual Net Income in USD
    -81 Million USD
    Annual Results for Period Ending
    Dec-2021 ending year
    Headquarters Country
    USA
    Yahoo @ Nasdaq
    Company Profile
    Inhibrx is a Clinical Stage Biotechnology company developed a diverse pipeline of therapeutic candidates specifically designed to leverage the power of core sdAb (single-domain antibody) platform and protein engineering expertise. The company annual revenue is 34.1 million USD and 80 employees as on 2020. The headquarters is in USA.
    Company Website
    INHIBRX, INC.

Share